Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

Overview of attention for article published in Blood, August 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

policy: 1 policy source
twitter: 38 X users
patent: 2 patents

facebook: 1 Facebook page
googleplus: 1 Google+ user

Readers on

mendeley: 150 Mendeley

So far, Altmetric has seen 44 X posts from 38 X users, with an upper bound of 216,654 followers.

3/9 HMA therapy for LR-MDS Modified doses of HMA therapy is being used for LR-MDS refractory to first-line therapies. Better responses are seen in pts with less transfusion burden. https://t.co/t70RWrciNy https://t.co/0NuEMIlctR https://t.co/fxybP…

@diberri @RenoHemonc @calliecoombsmd @TaylorJ_MD Response rate is reasonable per the Jabbour Blood 2017 paper (though HMA then no longer available for progression). https://t.co/TovyR33T7H

RT @doctorpemm: Randomized Ph2:Low-dose decitabine vs low-dose azacitidine in patients w/LR MDS |Jabbour ⁦@NicholasShortMD⁩ @doctorpemm⁩ ⁦@…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 40 additional X posts.